Sichuan Kelun Pharmaceutical Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Sichuan Kelun Pharmaceutical Co., Ltd. is a highly specialized innovative pharmaceutical group with an annual sales revenue of over 40 billion yuan, under the jurisdiction of Sichuan Kelun Pharmaceutical Co., Ltd., Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., and KlusPharmaInc More than 100 domestic and foreign enterprises, including Kolen in the United States, Kolen KAZ Pharmaceutical Co., Ltd. in Kazakhstan, and Sichuan Kolen Pharmaceutical Trading Group Co., Ltd. In 2017, Kolen ranked 155th among the top 500 manufacturing companies in China. In 2018, Kolen was awarded the "Manufacturing Single Champion Demonstration Enterprise" due to its global advantage in high-capacity injections. In 2022, Kolen ranked among the top three in China's pharmaceutical manufacturing industry. Sichuan Kelun Pharmaceutical Co., Ltd. was successfully listed on the Shenzhen Stock Exchange in June 2010, and immediately launched a 10 billion yuan industrial investment plan to implement the development strategy of "three engine driven, innovative growth". The first engine maintained the leading position of Kelun in the field of infusion through continuous industrial upgrading and variety structure adjustment; The second engine builds a competitive advantage in antibiotics from intermediates, raw materials, to formulations through innovative development and utilization of high-quality natural resources; The third engine is the ultimate driving force for the long-term development of the enterprise through the construction of a research and development system and diversified technological innovation. In the field of infusion, Kelun has achieved comprehensive industrial upgrading, with a dual profitability of high-end manufacturing and new materials, occupying a strategic highland of technological innovation and quality benchmark. Kolen has established a closed responsibility system for drug research and development, production and manufacturing, logistics transportation, and end use to ensure product quality and safety. Its leading products have been exported in bulk and have gained a high reputation in over 50 countries and regions. Kelun's independently developed upright bag is the first at home and abroad, with over 20 patents and won the National Science and Technology Progress Award. It has higher safety and cost-effectiveness than traditional infusion, and has enormous application value in reducing energy consumption and environmental protection, representing the direction of development of infusion products in China. In the field of antibiotics, the company has advanced westward and established Ili Chuanning Biotechnology Co., Ltd. to produce erythromycin thiocyanate and cephalosporin series intermediates. Through research and development experiments, upgrading and optimization, innovative cooperation, and the introduction of advanced domestic and foreign technology and equipment, Chuanning has been approved to build a national environmental protection antibiotic bacterial residue harmless treatment and resource utilization engineering technology center, solving the source problems of the antibiotic industry. In December 2022, Chuanning Biotechnology was successfully listed on the Shenzhen Stock Exchange's ChiNext board, fully entering the field of synthetic biology. Since its establishment, Kelun has successively invested more than 10 billion yuan in R&D and innovation, and established "National Enterprise Technology Center", "National Engineering Technology Research Center for Large Capacity Injection", "National Local Joint Engineering Laboratory for Large Capacity Injection". In 2022, Kelun Botai was approved by the National Development and Reform Commission to establish the only "National Engineering Research Center for Biotargeted Drugs" in China. As of now, Kelun has applied for over 1500 invention patents and obtained over 500 invention patent authorizations. It has launched the development of over 400 major drugs in multiple disease fields such as tumors, bacterial infections, and parenteral nutrition; Since 2017, it has been approved to list more than 20 items annually, becoming a leading generic pharmaceutical enterprise in China, and becoming a top supplier of national centralized drug procurement with a bid winning rate of over 90%; At the same time, nearly 20 Class 1 innovative drugs have entered the clinical research and application production stage, and more than ten innovative projects and patents have achieved overseas authorization for developed countries in Europe and America, fully entering a virtuous cycle of R&D investment and output. In 2022, Kelun Botai successfully reached three major licensing collaborations with multinational giant MSD, with a total contract amount of nearly 11.8 billion US dollars. Not only did it rank first in the history of international licensing transactions in the Chinese pharmaceutical industry, but it also ranked first on the 2022 TOP10 global pharmaceutical industry licensing cooperation list, laying a solid foundation for Kelun's position as the first player in the domestic innovative drug research and development field. In July 2023, Kelun Botai was successfully listed on the Hong Kong Stock Exchange, marking a new journey for Kelun's innovative research and development and global layout. Adhering to the corporate philosophy of "seeking truth through science and seeking goodness through ethics", Kelun has donated over 300 million yuan to social welfare, glorious causes, and charitable causes over the years, demonstrating Kelun's wealth quality concept and social justice sense, and demonstrating a good image of an excellent private enterprise developing healthily under market economy conditions. |
| Headquarter | Chengdu |
| Establish Date | 5/29/2002 |
| Listed Code | 002422.SZ |
| Listed Date | 6/3/2010 |
| Chairman | Liu Gexin. |
| CEO | Liu Sichuan. |
| Website | www.kelun.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
